Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05390515
PHASE4
Psoriatic Immune Response to Tildrakizumab
Sponsor: University of California, San Francisco
View on ClinicalTrials.gov
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2022-09-01
Completion Date
2028-09-01
Last Updated
2026-06-04
Healthy Volunteers
No
Conditions
Interventions
DRUG
Tildrakizumab Prefilled Syringe
IL-23 inhibitor
Locations (1)
University of California, San Francisco
San Francisco, California, United States